RNS Number: 0407S

Advanced Medical Solutions Grp PLC

12 June 2024

12 June 2024

Advanced Medical Solutions Group plc

("AMS" or the "Group")

Annual General Meeting

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, will hold its Annual General Meeting at 11.00 am today at the offices of Investec Bank plc, 30 Gresham Street, London, EC2V 7QP.

Chris Meredith, AMS's Chief Executive Officer, will give a short presentation at the Annual General Meeting. No new material information will be provided.

The results of the AGM will be announced to the London Stock Exchange and placed on the Group's website, in the usual way, as soon as practicable after the conclusion of the AGM.

- End -

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

ICR Consilium

Mary-Jane Elliott / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Gary Clarence / David Anderson

HSBC Bank plc (Broker) Sam McLennan / Joe Weaving / Stephanie Comish Tel: +44 (0) 1606 545508

Tel: +44 (0) 20 3709 5700

AMS@icrhealthcare.com

Tel: +44 (0) 20 7597 5970

Tel: 44 (0) 20 7991 8888

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand[®], RESORBA[®], LiquiBandFix8[®] and Seal-G[®]. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal[®] brand as well as under white label. Since 2019, the Group has made six acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and biodiagnostics materials, AFS Medical, an Austrian specialist surgical business, Connexicon, an Irish tissue adhesives specialist, and Syntacoll, a German specialist in collagen-based absorbable surgical implants.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 900 employees. For more information, please see www.admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.ms.com.

communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAFLFFDREILLIS